Class: Expansion (424)
Apparatus and method for culturing embryonic stem cells
Patent Number: 5449620Generation of knockout animals, as well as other chimeras, involves insertion of a gene-targeted embryonic stem cell into an embryo. This patent discloses a device that can physically hold the embryo so that injection of the stem cell can be performed with increased ease and accuracy.
Method preventing depletion of non-autologous hematopoietic cells and animal model systems for use thereof
Patent Number: 6770260This patent teaches depletion or inactivation of recipient macrophages using dichloromethylene diphosphonate in order to allow allogeneic or xenogeneic stem cell transplants and progeny of the stem cell transplants not to be rejected. The patent is very interesting since the inactivation of macrophages theoretically may also allow for inactivation of dendritic cells. If this occurs, then...
Myocardial grafts and cellular compositions useful for same
Patent Number: 6737054This patent teaches administration of stem cells, or cardiomyocytes, into areas of the heart that have been injured, including by infarction.
Stroma-derived stem cell proteoglycan growth factor
Patent Number: 5605829This patent provides a novel composition of matter that is useful for expansion of hematopoietic stem cells in vitro. The composition of matter is a unique proteoglycan that can selectively enhance the numbers of CD34+ stem cells when added to various in vitro culture systems.
Stroma-derived proteoglycan containing composition which promotes differentiation and maintains the self-renewal capacity of long-term bone marrow culture-initiating cells
Patent Number: 5523286This patent provides a proteoglycan matrix that can be used for growth and expansion of hematopoietic stem cells. Interestingly this patent promotes not just growth of CD34+ hematopoietic stem cells, but specifically, hematopoietic stem cells that are capable of supporting long term cultures. This patent can be used for expanding hematopoietic stem cells for...
Treatment of immunologic and hematologic disorders with IGFBP alone or complexed with IGF
Patent Number: 5527776This patent teaches that IGF-1 together with IGF Binding Protein-3 (IGFBP-3) can be used for stimulation of hematopoiesis and specifically upregulation of erythroid production in anemic patients. This is one example of a patent covering compounds that are traditionally seen as in the domain of endocrinologists, that are applied to...
Increase in hematopoietic progenitor cells in peripheral blood by transforming growth factor beta
Patent Number: 5426098This patent leverages the ability of TGF-beta to protect stem cells from cytotoxic agents by inhibiting proliferation of stem cells. Specifically, since chemotherapy kills proliferating cells, if the hematopoietic stem cells are first stopped from proliferating by administration of TGF-beta, then the hematopoietic system should be...
Preparation of serum-free suspensions of human hematopoietic cells or precursor cells
Patent Number: 6037174This is a patent on generation of neutrophil precursors and their expansion ex vivo. It may be interesting to use a patent such as this to generate allogeneic neutrophils for short term use after chemotherapy for patients that are immunocompromised so that they do not get infections. The question is whether administration of such allogeneic neutrophils would cause nephritis by virtue of...
Treatment of radiation-damaged bone marrow using galactosyl ceramides
Patent Number: 5767092The composition of matter described in this patent is actually a stimulator of NKT cells. In this patent, the composition, alpha galactosyl ceramide is described for the use of protecting the hematopoietic stem cell compartment from radiation or chemotherapy. It is unknown if these effects are directly mediated on the CD34+ hematopoietic...
Medium for long-term proliferation and development of cells
Patent Number: 5405772This patent is for a tissue culture media that is capable of expanding, as well as allowing differentiation of various cell types in vitro, including hematopoietic stem cells. The media is different than other approaches since it comprises several growth factors, as well as extracellular matrix components. Importantly the media does not use serum, this is applicable for clinical ex vivo...